Verapamil shows potential as a long-term oral treatment for type 1 diabetes


According to a new study published in Nature Communication.[1]

The study authors examined the impact of calcium channel blocker on type 1 diabetes patients for many years, first noticing the drug’s potential during research in animal models in 2014. This latest two-year analysis represents an update of the one-year results published in natural medicine in 2018.

The group’s research focused on evaluating blood serum samples from a small group of patients with type 1 diabetes. The patients took no diabetes medication other than their standard insulin regimen. during the study.

Overall, the use of verapamil delayed disease progression, improved endogenous beta cell function, and reduced insulin requirements. However, when patients stopped taking the drug, its impact seemed to fade, suggesting that a patient must continuously take verapamil to see consistent benefits.

Taking verapamil was also associated with normalization of levels of a serum protein called chromogranin A (CHGA). In fact, after one year, CHGA levels in patients on verapamil were comparable to healthy control patients. Patients taking a placebo did not see changes in chromogranin A levels, suggesting it may offer potential as a ‘therapeutic marker’.


About Author

Comments are closed.